At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02616 CSTONE PHARMA-B
Pre-opening 12-19 09:24:09
5.790
+0.000
0.00%
High5.790
Low5.790
Vol0.00
Open5.790
D1 Closing5.790
Amplitude0.00%
Mkt Cap8.55B
Tradable Cap8.55B
Total Shares1.48B
T/O0.00
T/O Rate0.00%
Tradable Shares1.48B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
CStone Pharmaceuticals (SEHK:2616): Valuation Check After GAVRETO Wins China National Reimbursement Drug List Approval
Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast
CStone Pharmaceuticals is a biopharmaceutical investment holding company focused on the research and development of anti-cancer therapies. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, sale of pharmaceutical products and provision of license of its intellectual property (IP) or commercialization license. The Company’s main products include targeted therapies, AYVAKIT (avapritinib) and GAVRETO (pralsetinib). The Company is also involved in the development and commercialization of immuno-oncology. The Company mainly conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.